The Advanced Renal Cell Carcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

“Advanced Renal Cell Carcinoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced Renal Cell Carcinoma Market.

Some of the key takeaways from the Advanced Renal Cell Carcinoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Advanced Renal Cell Carcinoma treatment therapies with a considerable amount of success over the years. 
• Advanced Renal Cell Carcinoma companies working in the treatment market are Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeutics, CoImmune, Infinity Pharmaceuticals, Chia Tai TianqingPharmaceutical, Hoffmann-La Roche, Merck Sharp & Dohme, Janux Therapeutics, AstraZeneca, Xencor, and others, are developing therapies for the Advanced Renal Cell Carcinoma treatment 

• Emerging Advanced Renal Cell Carcinoma therapies in the different phases of clinical trials are- OATD-02, DS-6000a, JANX008, NKT2152, CMN-001, IPI-549, TQB2450, Atezolizumab, Belzutifan, JANX 008, Volrustomig, XmAb819, and others are expected to have a significant impact on the Advanced Renal Cell Carcinoma market in the coming years.
• In July 2023, Toripalimab (Tuoyi) and axitinib (Inlyta) have been approved by China’s National Medical Products Administration (NMPA) for use as the first-line therapy for patients with metastatic or unresectable renal cell carcinoma (RCC). Data from an interim analysis of the phase 3 RENOTORCH study (NCT04394975), which indicated that the combination improved progression-free survival (PFS) compared to single-agent sunitinib (Sutent), are used to support the sNDA.
• In April 2023, In an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, Allogene Therapeutics provided interim data from its Phase 1 TRAVERSE trial of ALLO-316, the Company’s first AlloCAR T investigational product candidate for solid tumours. The novel anti-CD70 allogeneic CAR T-cell therapy ALLO-316’s preliminary antitumor activity and encouraging safety profile at low dose levels suggested that the regimen could represent a novel option for patients who have advanced clear cell renal cell carcinoma (ccRCC) that expresses CD70.
• In April 2023, The RENOTORCH research (NCT04394975), which was the subject of the disclosed interim analysis, has been completed, according to Shanghai Junshi Biosciences Co., Ltd. For the first-line therapy of patients with intermediate to high risk, distant metastatic renal cell carcinoma (“RCC”), unresectable or open-label, active-controlled phase 3 clinical research, RENOTORCH is assessing toripalimab in conjunction with axitinib. Based on an independent radiographic analysis, the Independent Data Monitoring Committee (IDMC) concluded that the primary endpoint of progression-free survival (“PFS”) had achieved the pre-established efficacy threshold.
• In January 2023, Teon Therapeutics disclosed that it had contracted with Merck to collaborate on clinical trials. The deal will evaluate Teon’s oral immune response modifier, TT-816, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), for patients with advanced solid tumours. The study is a two-armed, open-label, dose escalation and expansion clinical study that Teon is currently conducting.
• In December 2022, Exelixis announced the beginning of STELLAR-304, a phase 3 pivotal trial comparing sunitinib to zanzalintinib in patients with advanced non-clear cell renal cell carcinoma (nccRCC).
• In March 2022, In order to compare the effectiveness and safety of Belzutifan (MK-6482) plus pembrolizumab (MK-3475) versus placebo plus pembrolizumab in the adjuvant treatment of clear cell renal cell carcinoma (ccRCC) post-nephrectomy (MK-6482-022), Merck Sharp & Dohme started a multicenter, double-blind, randomised Phase III study.  
• In February 2020, In order to compare MK-6482 to everolimus in patients with advanced renal cell carcinoma who had progressed following past PD-1/L1 and VEGFtargeted treatments, Merck Sharp & Dohme started an open-label, randomised Phase III research.

Advanced Renal Cell Carcinoma Overview

Renal Cell Carcinoma (RCC) is the most prevalent form of kidney cancer, according to the Centres for Disease Control and Prevention (CDC) Trusted Source. The lining of the kidney’s tiny tubes, or tubules, is where this type of cancer grows. These tubules aid in the removal of waste from the circulation.

Get a Free Sample PDF Report to know more about Advanced Renal Cell Carcinoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-pipeline-insight

Emerging Advanced Renal Cell Carcinoma Drugs Under Different Phases of Clinical Development Include:

• OATD-02: Molecure S.A.
• DS-6000a: Daiichi Sankyo
• JANX008: Janux Therapeutics
• NKT2152: NiKang Therapeutics
• CMN-001: CoImmune
• IPI-549: Infinity Pharmaceuticals
• TQB2450: Chia Tai TianqingPharmaceutical
• Belzutifan: Merck Sharp & Dohme
• Atezolizumab: Hoffmann-La Roche
• Belzutifan: Merck Sharp & Dohme
• JANX 008: Janux Therapeutics
• Volrustomig: AstraZeneca
• XmAb819: Xencor

Advanced Renal Cell Carcinoma Route of Administration

Advanced Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Advanced Renal Cell Carcinoma Molecule Type

Advanced Renal Cell Carcinoma Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Advanced Renal Cell Carcinoma Pipeline Therapeutics Assessment

• Advanced Renal Cell Carcinoma Assessment by Product Type
• Advanced Renal Cell Carcinoma By Stage and Product Type
• Advanced Renal Cell Carcinoma Assessment by Route of Administration
• Advanced Renal Cell Carcinoma By Stage and Route of Administration
• Advanced Renal Cell Carcinoma Assessment by Molecule Type
• Advanced Renal Cell Carcinoma by Stage and Molecule Type

DelveInsight’s Advanced Renal Cell Carcinoma Report covers around 60+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Advanced Renal Cell Carcinoma product details are provided in the report. Download the Advanced Renal Cell Carcinoma pipeline report to learn more about the emerging Advanced Renal Cell Carcinoma therapies

Some of the key companies in the Advanced Renal Cell Carcinoma Therapeutics Market include:

Key companies developing therapies for Advanced Renal Cell Carcinoma are – Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Exelixis, BeiGene, Xencor, Teon Therapeutics, Bristol-Myers Squibb, SOTIO Biotech, Asher Biotherapeutics, Shanghai Junshi Biosciences, Surface Oncology, ProfoundBio, Portage Biotech, Novartis Pharmaceuticals, HiFiBiO, Inhibrx, Kymab, and others.

Advanced Renal Cell Carcinoma Pipeline Analysis:

The Advanced Renal Cell Carcinoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Renal Cell Carcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Renal Cell Carcinoma Treatment.
• Advanced Renal Cell Carcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Advanced Renal Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Renal Cell Carcinoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Advanced Renal Cell Carcinoma drugs and therapies

Advanced Renal Cell Carcinoma Pipeline Market Drivers

• Increasing Prevalence in Advanced Renal Cell Carcinoma, increase in the number of research and development activities are some of the important factors that are fueling the Advanced Renal Cell Carcinoma Market.

Advanced Renal Cell Carcinoma Pipeline Market Barriers

• However, side-effects associated with the treatment of Advanced Renal Cell Carcinoma, cost associated with the treatment and other factors are creating obstacles in the Advanced Renal Cell Carcinoma Market growth.

Scope of Advanced Renal Cell Carcinoma Pipeline Drug Insight    

• Coverage: Global
• Key Advanced Renal Cell Carcinoma Companies: Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeutics, CoImmune, Infinity Pharmaceuticals, Chia Tai TianqingPharmaceutical, Hoffmann-La Roche, Merck Sharp & Dohme, Janux Therapeutics, AstraZeneca, Xencor, and others
• Key Advanced Renal Cell Carcinoma Therapies: OATD-02, DS-6000a, JANX008, NKT2152, CMN-001, IPI-549, TQB2450, Atezolizumab, Belzutifan, JANX 008, Volrustomig, XmAb819, and others
• Advanced Renal Cell Carcinoma Therapeutic Assessment: Advanced Renal Cell Carcinoma current marketed and Advanced Renal Cell Carcinoma emerging therapies
• Advanced Renal Cell Carcinoma Market Dynamics: Advanced Renal Cell Carcinoma market drivers and Advanced Renal Cell Carcinoma market barriers 

Request for Sample PDF Report for Advanced Renal Cell Carcinoma Pipeline Assessment and clinical trials

Table of Contents

1. Advanced Renal Cell Carcinoma Report Introduction

2. Advanced Renal Cell Carcinoma Executive Summary

3. Advanced Renal Cell Carcinoma Overview

4. Advanced Renal Cell Carcinoma- Analytical Perspective In-depth Commercial Assessment

5. Advanced Renal Cell Carcinoma Pipeline Therapeutics

6. Advanced Renal Cell Carcinoma Late Stage Products (Phase II/III)

7. Advanced Renal Cell Carcinoma Mid Stage Products (Phase II)

8. Advanced Renal Cell Carcinoma Early Stage Products (Phase I)

9. Advanced Renal Cell Carcinoma Preclinical Stage Products

10. Advanced Renal Cell Carcinoma Therapeutics Assessment

11. Advanced Renal Cell Carcinoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Advanced Renal Cell Carcinoma Key Companies

14. Advanced Renal Cell Carcinoma Key Products

15. Advanced Renal Cell Carcinoma Unmet Needs

16 . Advanced Renal Cell Carcinoma Market Drivers and Barriers

17. Advanced Renal Cell Carcinoma Future Perspectives and Conclusion

18. Advanced Renal Cell Carcinoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services